| Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers MR Trusheim, ER Berndt, FL Douglas Nature reviews Drug discovery 6 (4), 287-293, 2007 | 665 | 2007 |
| Adaptive platform trials: definition, design, conduct and reporting considerations Nature Reviews Drug Discovery 18 (10), 797-807, 2019 | 260 | 2019 |
| From adaptive licensing to adaptive pathways: delivering a flexible life‐span approach to bring new drugs to patients HG Eichler, LG Baird, R Barker, B Bloechl‐Daum, F Børlum‐Kristensen, ... Clinical Pharmacology & Therapeutics 97 (3), 234-246, 2015 | 256 | 2015 |
| Quantifying factors for the success of stratified medicine MR Trusheim, B Burgess, SX Hu, T Long, SD Averbuch, AA Flynn, ... Nature reviews Drug discovery 10 (11), 817-833, 2011 | 134 | 2011 |
| “Threshold‐crossing”: a useful way to establish the counterfactual in clinical trials? HG Eichler, B Bloechl‐Daum, P Bauer, F Bretz, J Brown, LV Hampson, ... Clinical Pharmacology & Therapeutics 100 (6), 699-712, 2016 | 86 | 2016 |
| Alternative state-level financing for hepatitis C treatment—the “Netflix model” MR Trusheim, WM Cassidy, PB Bach Jama 320 (19), 1977-1978, 2018 | 82 | 2018 |
| Estimating the clinical pipeline of cell and gene therapies and their potential economic impact on the US healthcare system C Quinn, C Young, J Thomas, M Trusheim, ... Value in Health 22 (6), 621-626, 2019 | 75 | 2019 |
| Translational medicine guide transforms drug development processes: the recent Merck experience H Dolgos, M Trusheim, D Gross, JP Halle, J Ogden, B Osterwalder, ... Drug Discovery Today 21 (3), 517-526, 2016 | 70 | 2016 |
| Characterizing markets for biopharmaceutical innovations: do biologics differ from small molecules? MR Trusheim, ML Aitken, ER Berndt Forum for health economics & policy 13 (1), 2010 | 59 | 2010 |
| Surface-modified photochemistry. Preparation of silica-supported triiron dodecacarbonyl via irradiation of absorbed iron pentacarbonyl RL Jackson, MR Trusheim Journal of the American Chemical Society 104 (24), 6590-6596, 1982 | 50 | 1982 |
| Observation of photochemical intermediates in the low-temperature photolysis of silica-adsorbed iron carbonyl (Fe (CO) 5) MR Trusheim, RL Jackson The Journal of Physical Chemistry 87 (11), 1910-1916, 1983 | 49 | 1983 |
| PIPELINEs: creating comparable clinical knowledge efficiently by linking trial platforms MR Trusheim, AA Shrier, Z Antonijevic, RA Beckman, RK Campbell, ... Clinical Pharmacology & Therapeutics 100 (6), 713-729, 2016 | 42 | 2016 |
| Durable cell and gene therapy potential patient and financial impact: US projections of product approvals, patients treated, and product revenues CM Young, C Quinn, MR Trusheim Drug Discovery Today 27 (1), 17-30, 2022 | 36 | 2022 |
| Biologics are natural monopolies (part 1): why biosimilars do not create effective competition P Atteberry, PB Bach, JA Ohn, MR Trusheim Health Affairs Forefront, 2019 | 33 | 2019 |
| Market access of gene therapies across Europe, USA, and Canada: challenges, trends, and solutions E van Overbeeke, S Michelsen, M Toumi, H Stevens, M Trusheim, I Huys, ... Drug discovery today 26 (2), 399-415, 2021 | 31 | 2021 |
| Investigating investment in biopharmaceutical R&D PH Carter, ER Berndt, JA DiMasi, M Trusheim Nat Rev Drug Discov 15 (10), 673-4, 2016 | 31 | 2016 |
| Economic challenges and possible policy actions to advance stratified medicine MR Trusheim, ER Berndt Personalized Medicine 9 (4), 413-427, 2012 | 31 | 2012 |
| The clinical benefits, ethics, and economics of stratified medicine and companion diagnostics MR Trusheim, ER Berndt Drug Discovery Today 20 (12), 1439-1450, 2015 | 29 | 2015 |
| A Useful and Sustainable Role for N‐of‐1 Trials in the Healthcare Ecosystem HP Selker, T Cohen, RB D’Agostino, WH Dere, SN Ghaemi, PK Honig, ... Clinical Pharmacology & Therapeutics 112 (2), 224-232, 2022 | 25 | 2022 |
| Comparison of Stakeholder Metrics for Traditional and Adaptive Development and Licensing Approaches to Drug Development LG Baird, MR Trusheim, HG Eichler, ER Berndt, G Hirsch Therapeutic Innovation & Regulatory Science 47 (4), 474-483, 2013 | 24 | 2013 |
